TY - JOUR
T1 - Endothelial progenitor cells and circulating endothelial cells in early prostate cancer: A comparison with plasma vascular markers.
AU - Blann, Andrew
AU - Balakrishnan, B
AU - Shantsila, Eduard
AU - Ryan, PJ
AU - Lip, Gregory
PY - 2010/12/28
Y1 - 2010/12/28
N2 - BACKGROUND: Separate studies indicate that endothelial perturbation, as demonstrated by abnormal endothelial progenitor cells (EPCs), circulating endothelial cells (CECs), and plasma markers such as von Willebrand factor (vWf) and soluble E selectin (sEsel) are present in cancer. However, there are no reports where these indices are compared. Accordingly, we hypothesized altered EPCs and CECs in prostate cancer that would correlate with vWf, sEsel, and prostate specific antigen (PSA). METHODS: We recruited 29 men with biopsy proven prostate cancer, with 25 with benign prostate disease and 27 free of prostate disease. CECs were defined on flow cytometry as being CD34+, CD146+, CD45-, and CD309-, EPCs were similarly defined as being CD34+, CD309+, CD45-, and CD146-. vWf, sEsel, and PSA were measured by immunoassay. RESULTS: Despite higher PSA, sE-sel, and vWf in prostate cancer (all P 0.48, P
AB - BACKGROUND: Separate studies indicate that endothelial perturbation, as demonstrated by abnormal endothelial progenitor cells (EPCs), circulating endothelial cells (CECs), and plasma markers such as von Willebrand factor (vWf) and soluble E selectin (sEsel) are present in cancer. However, there are no reports where these indices are compared. Accordingly, we hypothesized altered EPCs and CECs in prostate cancer that would correlate with vWf, sEsel, and prostate specific antigen (PSA). METHODS: We recruited 29 men with biopsy proven prostate cancer, with 25 with benign prostate disease and 27 free of prostate disease. CECs were defined on flow cytometry as being CD34+, CD146+, CD45-, and CD309-, EPCs were similarly defined as being CD34+, CD309+, CD45-, and CD146-. vWf, sEsel, and PSA were measured by immunoassay. RESULTS: Despite higher PSA, sE-sel, and vWf in prostate cancer (all P 0.48, P
U2 - 10.1002/pros.21319
DO - 10.1002/pros.21319
M3 - Article
C2 - 21190239
SN - 1097-0045
VL - 71
SP - 1047
EP - 1053
JO - The Prostate
JF - The Prostate
ER -
